Literature DB >> 15987609

Rivastigmine for dementia associated with Parkinson's disease.

John Morgan1, Kapil D Sethi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987609     DOI: 10.1007/s11910-005-0070-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


× No keyword cloud information.
  19 in total

1.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response.

Authors:  Hulya Apaydin; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Dennis W Dickson
Journal:  Arch Neurol       Date:  2002-01

Review 2.  Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.

Authors:  Anthony E Lang; Jose A Obeso
Journal:  Lancet Neurol       Date:  2004-05       Impact factor: 44.182

3.  The association of incident dementia with mortality in PD.

Authors:  G Levy; M-X Tang; E D Louis; L J Côté; B Alfaro; H Mejia; Y Stern; K Marder
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

Review 4.  The role of radiotracer imaging in Parkinson disease.

Authors:  B Ravina; D Eidelberg; J E Ahlskog; R L Albin; D J Brooks; M Carbon; V Dhawan; A Feigin; S Fahn; M Guttman; K Gwinn-Hardy; H McFarland; R Innis; R G Katz; K Kieburtz; S J Kish; N Lange; J W Langston; K Marek; L Morin; C Moy; D Murphy; W H Oertel; G Oliver; Y Palesch; W Powers; J Seibyl; K D Sethi; C W Shults; P Sheehy; A J Stoessl; R Holloway
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

5.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Authors:  I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

6.  Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.

Authors:  Mariese A Hely; John G L Morris; Wayne G J Reid; Robert Trafficante
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

Review 7.  Dementia in Parkinson's disease: cause and treatment.

Authors:  Murat Emre
Journal:  Curr Opin Neurol       Date:  2004-08       Impact factor: 5.710

8.  Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations.

Authors:  Hani T S Benamer; Wolfgang H Oertel; Jim Patterson; Donald M Hadley; Oliver Pogarell; H Höffken; A Gerstner; Donald G Grosset
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

9.  Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study.

Authors:  Nicolaas I Bohnen; Daniel I Kaufer; Larry S Ivanco; Brian Lopresti; Robert A Koeppe; James G Davis; Chester A Mathis; Robert Y Moore; Steven T DeKosky
Journal:  Arch Neurol       Date:  2003-12

10.  How common is dementia in Parkinson's disease?

Authors:  R G Brown; C D Marsden
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.